The structure of JNK3 in complex with small molecule inhibitors: Structural basis for potency and selectivity

被引:115
作者
Scapin, G
Patel, SB
Lisnock, J
Becker, JW
LoGrasso, PV
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Metab Dis, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Mol Neurosci, San Diego, CA 92121 USA
来源
CHEMISTRY & BIOLOGY | 2003年 / 10卷 / 08期
关键词
D O I
10.1016/S1074-5521(03)00159-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The c-Jun terminal kinases (JNKs) are members of the mitogen-activated protein (MAP) kinase family and regulate signal transduction in response to environmental stress. Activation of JNK3, a neuronal-specific isoform, has been associated with neurological damage, and as such, JNK3 may represent an attractive target for the treatment of neurological disorders. The MAP kinases share between 50% and 80% sequence identity. In order to obtain efficacious and safe compounds, it is necessary to address the issues of potency and selectivity. We report here four crystal structures of JNK3 in complex with three different classes of inhibitors. These structures provide a clear picture of the interactions that each class of compound made with the kinase. Knowledge of the atomic interactions involved in these diverse binding modes provides a platform for structure-guided modification of these compounds, or the de novo design of novel inhibitors that could satisfy the need for potency and selectivity.
引用
收藏
页码:705 / 712
页数:8
相关论文
共 43 条
[1]   New inhibitors of p38 kinase [J].
Boehm, JC ;
Adams, JL .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37
[2]   Chemical inhibitors of protein kinases [J].
Bridges, AJ .
CHEMICAL REVIEWS, 2001, 101 (08) :2541-2571
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   Ribbons [J].
Carson, M .
MACROMOLECULAR CRYSTALLOGRAPHY, PT B, 1997, 277 :493-505
[5]   Mammalian MAP kinase signalling cascades [J].
Chang, LF ;
Karin, M .
NATURE, 2001, 410 (6824) :37-40
[6]   Structure-based design of cyclin-dependent kinase inhibitors [J].
Davies, TG ;
Pratt, DJ ;
Endicott, JA ;
Johnson, LN ;
Noble, MEM .
PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) :125-133
[7]   Protein kinase inhibitors: emerging pharmacophores 1997-2000 [J].
Dumas, J .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (03) :405-429
[8]   ALTERED GENE-EXPRESSION IN NEURONS DURING PROGRAMMED CELL-DEATH - IDENTIFICATION OF C-JUN AS NECESSARY FOR NEURONAL APOPTOSIS [J].
ESTUS, S ;
ZAKS, WJ ;
FREEMAN, RS ;
GRUDA, M ;
BRAVO, R ;
JOHNSON, EM .
JOURNAL OF CELL BIOLOGY, 1994, 127 (06) :1717-1727
[9]   Conversion of SB 203580-insensitive MBP kinase family members to drug-sensitive forms by a single amino-acid substitution [J].
Eyers, PA ;
Craxton, M ;
Morrice, N ;
Cohen, P ;
Goedert, M .
CHEMISTRY & BIOLOGY, 1998, 5 (06) :321-328
[10]  
FITZGERALD CE, 2003, IN PRESS NAT STRUCT